Recurrent epithelial ovarian cancer: an update on treatment.
نویسندگان
چکیده
An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
منابع مشابه
Update of randomized trials in recurrent disease.
In the absence of significant advance in first-line therapy until recently, the increased knowledge of how to manage relapse accounts for most of the advances observed in ovarian cancer during the last 10 years. In addition, a large number of new drugs, mostly in the category of 'targeted therapy', are currently being tested in the setting of recurrent ovarian and are expected to change the cou...
متن کاملLONG TERM ORAL ETOPOSIDE AS SECOND-LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY
Background: The activity and toxicity of etoposide in women with recurrent ovarian cancer was evaluated in a case series of women with recurrent ovarian cancer who had measurable disease, Methods: All patients had plior platinum-based chemotherapy and developed progressive disease, Etoposide was given as 50mg/day for 21 days every 4 weeks until progression of disease or prohibitive toxicit...
متن کاملEvaluation of the Anticancer Effect of Xanthium Strumarium Root Extract on Human Epithelial Ovarian Cancer Cells Using 1H NMR-Based Metabolomics
Epithelial Ovarian cancer is the leading cause of cancer mortality among women all over the world. As chemotherapeutics has many side effects, researchers have focused on the potential use of medicinal plants as natural antitumor agents. Xanthium strumarium studied in this work as an herbal anticancer agent. This study aimed to evaluate the antitumor effect and metabolic alterations ca...
متن کاملترکیب جم سیتابین- کربوپلاتین در درمان عود سرطان تخمدان: یک مطالعه آیندهنگر
Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 !mso]> st1":*{behavior:url(#ieooui) } /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal" mso-tst...
متن کاملTargeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer
Chemoresistance is the main challenge for the recurrent ovarian cancer therapy and responsible for treatment failure and unfavorable clinical outcome. Understanding mechanisms of chemoresistance in ovarian cancer would help to predict disease progression, develop new therapies and personalize systemic therapy. In the last decade, accumulating evidence demonstrates that epithelial-mesenchymal tr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Oncology
دوره 27 4 شماره
صفحات -
تاریخ انتشار 2013